Michel Pavic
Overview
Explore the profile of Michel Pavic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
562
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Parent-Roberge H, Fontvieille A, Marechal R, Wagner R, Fulop T, Pavic M, et al.
Brain Behav Immun Health
. 2024 Feb;
2:100016.
PMID: 38377414
Methods: Twenty older non-metastatic cancer patients initiating chemotherapy and/or hormone therapy were randomly assigned to 12 weeks of supervised, combined exercise or a control group (static stretching). Primary outcomes were...
12.
Toure M, Pavic M, Poder T
Med Care
. 2023 Jun;
61(8):536-545.
PMID: 37308990
Background: Quality-adjusted life-year instruments help comparison among programs by capturing their effects in terms of utility. Generic instruments are applicable to everyone, and for this reason, they are known to...
13.
Wong P, Masucci L, Florescu M, Plourde M, Panet-Raymond V, Pavic M, et al.
Neurooncol Adv
. 2023 Apr;
5(1):vdad018.
PMID: 37025758
Background: Anti-PD-1 has activity in brain metastases (BM). This phase II open labeled non-randomized single arm trial examined the safety and efficacy of combining nivolumab with radiosurgery (SRS) in the...
14.
Fontvieille A, Parent-Roberge H, Marechal R, Fulop T, Riesco E, Pavic M
J Geriatr Oncol
. 2022 Jun;
13(7):1070.
PMID: 35697606
No abstract available.
15.
Genicon C, Guilloton L, Pavic M, Le Moigne F
Joint Bone Spine
. 2021 Dec;
89(4):105324.
PMID: 34906698
No abstract available.
16.
Joly-Mischlich T, Maltais S, Tetu A, Delorme M, Boilard B, Pavic M
J Oncol Pharm Pract
. 2021 Nov;
29(1):88-95.
PMID: 34751068
Introduction: Prior to implementing a new computerized prescription order entry (CPOE) application, the potential risks associated with this system were assessed and compared to those of paper-based prescriptions. The goal...
17.
Gahide G, Pavic M, Sirois C, Sirois M, Poon J, Grondin-Beaudoin B, et al.
J Vasc Interv Radiol
. 2021 Sep;
32(12):1701-1703.
PMID: 34547474
No abstract available.
18.
Richardson P, Schjesvold F, Weisel K, Moreau P, Anderson Jr L, White D, et al.
Eur J Haematol
. 2021 Sep;
108(1):73-83.
PMID: 34496096
Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with...
19.
Tessier C, Allard T, Boudreault J, Kaedbey R, Ethier V, Fortin F, et al.
Curr Oncol
. 2021 Jun;
28(3):2029-2039.
PMID: 34073289
Background-smoldering multiple myeloma (SMM) risk of progression to multiple myeloma (MM) is highly heterogeneous and several models have been suggested to predict this risk. Lakshman et al. recently proposed a...
20.
Bringhen S, Pour L, Vorobyev V, Vural F, Warzocha K, Benboubker L, et al.
Leuk Res
. 2021 Apr;
104:106576.
PMID: 33839618
Patients with relapsed/refractory multiple myeloma (RRMM) experience several relapses, and become refractory to successive therapies. In the ICARIA-MM trial (NCT02990338), isatuximab plus pomalidomide-dexamethasone prolonged median progression-free survival (PFS) in patients...